Zobrazeno 1 - 10
of 135
pro vyhledávání: '"Anna Mae Diehl"'
Autor:
Manal F. Abdelmalek, Jeongeun Hyun, Steven R. Patierno, Rebecca Caffrey, Cynthia A. Moylan, Muthana Al Abo, Anna Mae Diehl, Xiyou Zhou, Seh-Hoon Oh, Arun J. Sanyal, Kun Xiang, Rajesh Kumar Dutta, Raquel Maeso-Díaz, Jennifer A. Freedman
Publikováno v:
J Hepatol
Background & Aims Non-alcoholic fatty liver disease (NAFLD), the hepatic correlate of the metabolic syndrome, is a major risk factor for hepatobiliary cancer (HBC). Although chronic inflammation is thought to be the root cause of all these diseases,
Autor:
Colby Ayers, Kara Wegermann, Vanessa Blumer, Robert W. McGarrah, Ambarish Pandey, Cynthia A. Moylan, Anna Mae Diehl, Tarek Bekfani, Anthony E. Peters, Manal F. Abdelmalek, Marat Fudim, Justin L. Grodin
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 842-848 (2021)
ESC Heart Failure
ESC Heart Failure
Aims Non‐alcoholic fatty liver disease leads to progressive liver fibrosis and appears to be a frequent co‐morbid disease in heart failure with preserved ejection fraction (HFpEF). It is well known that liver fibrosis severity predicts future liv
Autor:
Anna Mae Diehl, Oliver Glass, Elizabeth Bechard, Jane F. Pendergast, Cynthia D. Guy, Daniel Liu, Manal F. Abdelmalek
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 6, Iss 2, Pp 334-344 (2022)
Hepatology Communications, Vol 6, Iss 2, Pp 334-344 (2022)
Exercise is a foundational treatment for nonalcoholic fatty liver disease (NAFLD); however, the majority of patients are unable to initiate and maintain effective exercise habits and remain at increased risk for progressive liver disease. Barriers an
Autor:
Anna Mae Diehl, Nezam H. Afdhal, Andrew J. Muir, Jaime Bosch, G. Mani Subramanian, Zachary Goodman, Raul Aguilar Schall, Arun J. Sanyal, Stephen A. Harrison, Stephen H. Caldwell, B. Mccolgan, Maria Stepanova, Manal F. Abdelmalek, Robert P. Myers, Vlad Ratziu, Zobair M. Younossi, Mitchell L. Shiffman
Publikováno v:
Journal of Hepatology. 69:1365-1370
Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis
Autor:
Mustafa R. Bashir, David A. Rizzieri, Keith M. Sullivan, Mohammad Chaudhry, Louis F. Diehl, Mitchell E. Horwitz, Ko K. Maung, Kristi Romero, Anna Mae Diehl, Kelly Corbet, Anthony D. Sung, Stefanie Sarantopoulos, Richard D. Lopez, Sendhilnathan Ramalingam, Yi Ren, Cristina Gasparetto, Gwynn D. Long, Sin-Ho Jung, Taewoong Choi, Nelson J. Chao
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 9, p e0238824 (2020)
PLoS ONE, Vol 15, Iss 9, p e0238824 (2020)
Allogeneic-HCT (allo-HCT), while potentially curative, can result in significant complications including graft versus host disease (GVHD). Prior studies suggest that metabolic syndrome may be one risk factor for GVHD. We hypothesized that hepatic ste
Autor:
Geoffrey I. Scott, Varun Chandrashekaran, Prakash S. Nagarkatti, Diana Kimono, Samir Raychoudhury, Mitzi Nagarkatti, Sutapa Sarkar, Anna Mae Diehl, Firas Alhasson, Ratanesh Seth, Saurabh Chatterjee, Muayad Albadrani, Diptadip Dattaroy
Publikováno v:
Redox Biology, Vol 17, Iss, Pp 1-15 (2018)
High circulatory insulin and leptin followed by underlying inflammation are often ascribed to the ectopic manifestations in non-alcoholic fatty liver disease (NAFLD) but the exact molecular pathways remain unclear. We have shown previously that CYP2E
Publikováno v:
Critical Reviews in Biochemistry and Molecular Biology. 53:264-278
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of obesity-associated liver diseases and it has become the major cause of cirrhosis in the Western world. The high prevalence of NAFLD-associated advanced liver disease reflects both the
Publikováno v:
Journal of Hepatology. 68:550-562
Liver disease remains a leading cause of mortality worldwide despite recent successes in the field of viral hepatitis, because increases in alcohol consumption and obesity are fuelling an epidemic of chronic fatty liver disease for which there are cu
Autor:
Kara Wegermann, Ayako Suzuki, Alisha M. Mavis, Manal F. Abdelmalek, Anna Mae Diehl, Cynthia A. Moylan
Publikováno v:
Hepatology. 73:1625-1625
We appreciate de Zegher and Ibanez calling attention to the association between non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). As de Zegher and Ibanez rightly point out, NAFLD can occur in children and adolescents w
Autor:
Gregory A. Michelotti, Wolfgang Liedtke, Mitzi Nagarkatti, Saurabh Chatterjee, Firas Alhasson, Varun Chandrashekaran, Prakash S. Nagarkatti, P. Darwin Bell, Ratanesh Seth, Diptadip Dattaroy, Suvarthi Das, Anna Mae Diehl
Publikováno v:
Free Radical Biology and Medicine. 102:260-273
NAFLD is a clinically progressive disease with steatosis, inflammation, endothelial dysfunction and fibrosis being the stages where clinical intervention becomes necessary. Lack of early biomarkers and absence of a FDA approved drug obstructs efforts